Introduction {#ss1}
============

Chronic pain affects approximately 20% of the adult population in developed countries[@b1; @b2; @b3] and has a profound effect upon individuals, economies and society in general, yet remains under-diagnosed and under-treated[@b4] ^,^ [@b5]. Relevant factors are that doctors' training in pain management is often insufficient or almost non-existent[@b6] ^,^ [@b7], many have misconceptions about the prescription of opioids[@b8], and improving clinical knowledge could lead to better outcomes[@b9]. The prevalence of chronic pain increases with age, and by the age of 70 pain affects 79% of women and 53% of men[@b10]. The burgeoning elderly population -- the European Commission predicts that almost a quarter of the population of its 27 member states will be more than 65 years of age by 2035[@b11] -- suggests that, without an increased knowledge of pain physiology and the wider adoption of best pain management practice, the shortfall in care for these patients is likely to become rapidly worse.

 The international CHANGE PAIN Advisory Board of leading pain specialists meets regularly to discuss specific topics to try and achieve consensus on measures that could enhance the care of pain patients. Aware of the urgent and growing need to improve the management of chronic cancer and non-cancer pain, at its meeting on 17th and 18th June 2011 the Advisory Board reviewed current knowledge of the development of chronic pain and the advantages of a multidisciplinary team approach to the provision of pain therapy, in order to support its wider dissemination. A number of consensus points were agreed as being of particular importance. Following relevant presentations to the Board, potential points were discussed and groups of Board members then answered pre-prepared questions on the topics via a local area network. Analysis of the answers was followed by more discussion, and draft versions of the consensus points were further refined by the authors.

The development of chronic pain {#ss2}
===============================

Nociceptive and neuropathic pain {#ss3}
--------------------------------

Nociceptive pain is usually transient and may be either somatic or visceral. As a result of tissue damage and inflammation -- caused by conditions such as trauma[@b12], arthritis[@b13], or cancer[@b14] -- peripheral nociceptors are activated by molecules such as prostaglandins, substance P, histamine and bradykinin. These cause depolarization of the nociceptors that is transmitted to the spinal cord via slow, non-myelinated C fibers and fast, myelinated Aδ fibers. In the spinal cord, the incoming signals are then modulated, transmitted to second order neurons by neurotransmitters, and passed to the brain stem via ascending pathways ([Figure 1](#f1){ref-type="fig"}). For example, glutamate has an excitatory effect and enhances pain, whereas gamma-aminobutyric acid (GABA) has an inhibitory effect and reduces pain[@b15] ^,^ [@b16]. The brain stem essentially acts as a mediator of transmission to higher centers, where the pain signals are interpreted[@b17] ^,^ [@b18]. Pain perception is simultaneously modified by descending pain pathways. Information about noxious stimuli is transmitted from the limbic system and midbrain structures down through the periaqueductal grey to the brainstem, especially the rostroventral medulla[@b19]. Here the signals are filtered before passing to the dorsal horn of the spinal cord at the level of the incoming pain signal. Key neurotransmitters in the descending pathways are noradrenaline, which reduces pain, and serotonin (or 5-hydroxytryptamine), which may have both facilitatory and inhibitory functions[@b20] ^,^ [@b21].

![Ascending and descending pathways.](CMO-29-1127-g001){#f1}

In 2009, the definition of neuropathic pain was revised by an expert committee of the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG); it is now "pain arising as direct consequence of a lesion or disease affecting the somatosensory system"[@b22]. The cause may be, for example, trauma, surgery, diabetes, herpes zoster virus, alcohol or cancer. As a result, there is a switch in the phenotype of the sensory neurons and their pain signaling mechanisms. Alterations in the function of sodium channels (which generate pain signals)[@b23], potassium channels (which inhibit pain signals)[@b24] and calcium channels (which facilitate transmitter release) have been reported[@b25]. The pain produced is typically burning, tingling or 'electric' in character, and may be accompanied by allodynia -- in which normally non-painful stimuli evoke pain -- and hyperalgesia[@b18]. Neuropathic pain tends to be more severe than nociceptive pain and also more difficult to treat[@b26].

It should be noted that both nociceptive and neuropathic pain can coexist, in conditions such as back pain and cancer pain, and both may become chronic. It is important that neuropathic pain is not confused with sensitization; the distinction between central or peripheral sensitization and neuropathic pain is often not made, although the underlying pathology is different. Understanding the differences between nociceptive and neuropathic pain, and how they develop, is essential if the patient is to receive the most effective pain therapy.

Consensus point {#ss4}
===============

Understanding current theories of the development of chronic pain is crucial for everyone involved in pain treatment.

Peripheral sensitization {#ss5}
------------------------

Nociceptive pain is normally experienced as the result of noxious stimuli acting on high threshold nociceptors. In peripheral sensitization, the threshold for activation is reduced and membrane excitability increases[@b27]. The presence of injury or disease causes the local release of inflammatory mediators -- protons, adenosine triphosphate, prostaglandins, substance P and histamine -- that also attract immune cells[@b28]. These cells, in turn, release cytokines such as interleukin-1β and tumor necrosis factor (TNF), which elicit action potentials by increasing sodium and calcium currents at the nociceptor terminal[@b27]. This inflammatory response may be accompanied by ectopic action potentials (i.e. where there is no peripheral stimulus), particularly when there has been damage to neurons.

Central sensitization {#ss6}
---------------------

If the transmission of pain signals from the periphery to the spinal cord persists, changes may occur in the CNS and produce central sensitization. This can be defined as pain hypersensitivity that may arise from a reduced threshold for activation and an abnormal amplification of sensory signaling within the CNS[@b29]. Although nociceptive stimulation from the periphery may be both increased and prolonged initially, the pain experience is disconnected from the peripheral pathology. The process of central sensitization may initially be reversible[@b30], but it can also become permanent. Its effect at central sites can lead to the establishment of co-morbidities such as depression and anxiety[@b31], as well as to hypersensitivity to other stimuli or the development of more diffuse pain states.

A number of different mechanisms are involved. The development of central sensitization may begin with a nociceptive input from the periphery to a synapse in the dorsal horn of the spinal cord, causing the pre-synaptic neuron to release substance P and glutamate into the synaptic cleft, lowering the threshold of neuronal excitability[@b29]. By combining with post-synaptic ion channel receptors, the most important of which are *N*-methyl *D*-aspartate (NMDA) receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, these compounds enable the pain signal to be transmitted upwards to the thalamus. Simultaneous activation of Toll-like receptor 4 (TLR4) on microglia cells leads to the release of inflammatory modulators. In addition, pre-synaptic NMDA receptors play a part; blocking these receptors with ketamine reduces the release of substance P and excitatory amino acids. If the nociceptive input from the periphery persists, the prolonged activation of NMDA receptors is accompanied by an increase in NMDA receptor density and the experience of pain is enhanced[@b32] ^,^ [@b33].

Allodynia, hyperalgesia and spontaneous pain may be produced by central sensitization, but there are additional signs and symptoms. Secondary hyperalgesia (i.e. increased sensitivity to pain in the undamaged tissue around the original injury) indicates central sensitization. Another characteristic is facilitated temporal summation or 'wind-up', in which repeated identical stimuli become increasingly painful in spite of unchanged stimulus intensity[@b29] ^,^ [@b34]. NMDA receptors are involved in this process because 'wind-up' can be countered with ketamine[@b35]. Other clinical features of central sensitization are the expansion of areas of referred pain (a spinal phenomenon resulting from the involvement of neurons other than those receiving a persistent nociceptive input), impaired descending inhibition and enhanced descending facilitation.

In the case of 'wind-up', pre-synaptic NMDA receptors respond to short-term ketamine exposure and produce analgesia. However, it is important to note that this response to ketamine is not synonymous with central sensitization, which is a phenomenon of post-synaptic NMDA receptors. Central sensitization is relatively resistant to ketamine and requires long-term exposure to be effective ([Figure 2](#f2){ref-type="fig"}). A 1 hour infusion produces over 50% pain relief, but the effect is short-lived and lasts less than 48 hours[@b36]. Some evidence suggests that longer infusions (±100 hours) are required to produce desensitization, but can produce long-term relief from chronic pain which lasts several months; for example, in patients with complex regional pain syndrome[@b37]. Thus a persistent effect after ketamine withdrawal may be regarded as a sign of NMDA activity and sensitization.
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There is also evidence that defective descending inhibitory control (DIC) is present in various chronic pain syndromes[@b19] ^,^ [@b38; @b39; @b40], and may itself be a cause of central sensitization. The presence of defective DIC may be identified by techniques such as offset analgesia, a temporal contrast mechanism for studying endogenous pain relief[@b41], and diffuse noxious inhibitory control (DNIC), a spatial contrast mechanism which utilizes two stimuli.

Chronic pain: diagnosis and mechanism-based treatment {#ss7}
=====================================================

Chronic pain has traditionally been defined solely on the basis of its duration; for example, as "pain which persists past the normal time of healing. With non-malignant pain, three months is the most convenient point of division between acute and chronic pain, but for research purposes six months will often be preferred"[@b42]. Consequently, diagnosis is often similarly based on duration, but this takes no account of the specific causative mechanisms or clinical significance. Knowledge of the causative mechanisms is important, in order to institute the most appropriate treatment strategy, and unless the correct underlying mechanisms are addressed analgesic therapy is likely to prove ineffective[@b43]. Identification of the multiple mechanisms responsible for the production of pain syndromes and their molecular components has been a major advance in our understanding of pain[@b18]. However, identification of the pathophysiological mechanisms responsible for distinct pain syndromes is incomplete at present, and multiple mechanisms may coexist in many pain conditions, so combination therapy is often indicated[@b18]. There remains a need for valid and reliable assessment tools which can accurately link specific clinical signs and symptoms to a particular mechanism[@b44].

In recent years, a definition based on a prognostic risk score has been shown to have better predictive validity for pain outcomes than pain duration alone[@b45]. By emphasizing factors other than pain (e.g. activity limitation and depression) this definition may suggest possible avenues for improving outcomes in addition to simply controlling pain (for example, increasing exercise levels and improving mood)[@b45].

The diagnosis of chronic pain requires a multiple step approach, with different tests and investigations being applied at each step. To complement a medical history and physical examination, the physician may use a questionnaire to aid diagnosis. Examples include painDETECT, which can identify the presence of a neuropathic pain component in patients suffering from low back pain with high sensitivity and specificity[@b46], and the Douleur Neuropathique 4 (DN4)[@b47]. Other assessment tools include the Standardized Evaluation of Pain (StEP), which uses a structured interview and standardized examination to differentiate pain phenotypes independent of aetiology[@b48]. More technical and sophisticated techniques are under evaluation: for example, Quantitative Sensory Testing[@b49] analyzes perception in response to external stimuli of controlled intensity, and is especially suitable for quantifying hyperalgesia and allodynia in painful neuropathic syndromes.

Clinical investigations might include X-rays, magnetic resonance imaging or computed tomography. Blood tests may indicate the presence of inflammation or infection. In special cases, nerve conduction studies might be used to determine any changes in amplitude or conduction velocity, and somatosensory evoked potential studies to indicate dysfunction of the somatosensory pathways. The function of small fiber (Aδ and C) sensory pathways can be specifically evaluated using laser evoked potentials[@b50] or the contact heat evoked potential stimulator (CHEPS)[@b51]. Suspected small fiber neuropathy is rarely an indication for nerve biopsy, and should instead be investigated with skin biopsy, allowing visualization and quantification of intra-epidermal nerve fibres[@b52]. Finally, there is a role for pharmacological intervention in diagnosis; for example, the local application of lidocaine at the peripheral origin of pain, different formulations of opioids, or drugs like amitriptyline and tapentadol which may help to restore descending inhibitory control.

Consensus point {#ss8}
===============

Different types of investigation can help determine the causative mechanisms involved in chronic pain.

The multidisciplinary approach to treatment {#ss9}
===========================================

The biopsychosocial model {#ss10}
-------------------------

This model of pain, first proposed by Engel[@b53], is now widely accepted as the most heuristic approach to understanding the true nature of chronic pain. It is based on the concept that pain is essentially an interactive psychophysiological behavior pattern that cannot be divided into distinct psychosocial and physical components, and that psychological and social factors must therefore be taken into account when considering treatment[@b54]. Supporting evidence that an appreciation of the biopsychosocial model is essential for understanding the patient with chronic pain comes from a number of studies. For example, catastrophizing and unemployment have been shown to be amongst the strongest predictors of disability one year later in patients with either acute or chronic low back pain[@b55] ^,^ [@b56]. Other psychological and social factors that are important prognostic indicators of future pain include anxiety and high levels of distress[@b57] ^,^ [@b58], and self-rated health[@b59]. Furthermore, numerous studies have demonstrated a beneficial effect of behavioral and psychological interventions in the management of chronic low back pain[@b60; @b61; @b62; @b63]. These results strongly indicate that psychological treatment needs to be integrated with other therapeutic components, such as physical therapy and medication management, or the effectiveness of treatment will be compromised.

Consensus point {#ss11}
===============

A biopsychosocial approach is essential to understanding the patient with chronic pain.

The multidisciplinary team {#ss12}
--------------------------

The complexity of the pain experience means that the diverse aspects of chronic pain are best treated by a multidisciplinary team, enabling patients to benefit from the co-ordination and integration of various medical disciplines and treatment modalities. They are more likely to benefit from an early and accurate diagnosis, and to receive various therapies specifically tailored to their individual needs. Each team member should have a basic knowledge of the physiology and clinical practices associated with chronic pain, and of the expertise of fellow team members. Regular communication between all team members is essential, to help ensure a consistency of approach and good continuity of care, whilst simultaneously avoiding inadequate pain control, unnecessary specialist visits, redundant testing and increased costs. More information about many important aspects of multidisciplinary pain treatment can be found in the booklet 'Towards a multidisciplinary team approach in chronic pain management', which was developed by members of the CHANGE PAIN Advisory Board and is now available online at [www.change-pain.com](www.change-pain.com).

Consensus point {#ss13}
===============

Multidisciplinary management of chronic pain requires a core multidisciplinary team of healthcare professionals.

The structure of multidisciplinary teams varies considerably, but the core team generally consists of three physicians (e.g. primary care physician, anesthesiologist/pain specialist and psychiatrist), plus non-physicians (e.g. psychologist, physiotherapist and nurses)[@b64]. The primary care physician has a key role, acting as gatekeeper of the treatment strategy, as well as being responsible for the long-term care of the patient and referral where necessary. Other specialists that often play a role in the core team include neurologists, rheumatologists, orthopedists, neurosurgeons and rehabilitation therapists[@b64]. As chronic pain affects all aspects of daily living, there is a wider team of medical and non-medical specialists which is more flexible in structure and often provides support for the patient on an *ad hoc* basis. Members might include pharmacists, dieticians, complementary therapists, educational therapists, occupational therapists and medical social workers.

Multidisciplinary teams are generally managed by the anesthesiologist/pain specialist, who also co-ordinates patients' individual treatment plans[@b65]. Many teams operate syndrome-orientated clinics, such as headache clinics and low back pain centers. Consultations usually involve two or more specialists, and this collaborative approach is also demonstrated by regular joint consultations and pain conferences, which review the pain management and progress of individual patients. These scheduled meetings facilitate optimization of patient care, and provide an opportunity for the referral of patients to a different member of the multidisciplinary team where it is deemed appropriate.

This philosophy has been put into practice in Belgium, where nine multidisciplinary centers for treating chronic pain were established in 2005[@b66]. Each had to include at least three medical and three paramedical specialties, and the Director had to have both extra training and at least three years' full time experience in pain management. The subsequent success of these centers led to the creation of 36 new multidisciplinary teams to treat patients with early stage pain, using a biopsychosocial approach agreed with the Belgian Pain Society. Each includes a pain specialist and a psychiatrist, and all hospital services are available to the team. These measures are complemented by a third mechanism -- established at 73 different locations -- to tackle pain as early as possible, by using a specially trained nurse to identify patients at risk of developing chronic pain and referring them to a pain specialist for a full diagnosis[@b66].

What are the benefits? {#ss14}
----------------------

Many of the advantages of the multidisciplinary approach come from the streamlining and rationalization of pain management. It offers an early, multidimensional diagnosis of chronic pain and a rapid initiation of evidence-based therapy according to an individualized treatment plan. A wide array of pharmacological and non-pharmacological treatment options is made available, which the patient can discuss with the various specialists involved. Duplication of investigations is avoided and treatment failure can be picked up early.

For the patient, there is continuity of care, delivered in a programmed and co-ordinated manner. Studies have consistently reported reductions in pain intensity following multidisciplinary pain treatment in patients with chronic low back pain[@b61] ^,^ [@b67], fibromyalgia[@b68] and temporomandibular disorders[@b69]. Recent evidence-based treatment guidelines recommend a multidisciplinary approach for treating several chronic pain conditions, including low back pain[@b70] and osteoarthritis[@b71]. Furthermore, treatment leads not only to pain relief but also to improvements in physical functioning, quality of life, emotional stress and behavioral outcomes. These, in turn, confer psychological advantages such as greater self-esteem.

In clinical trials, multidisciplinary pain treatment has been shown to facilitate the regaining of physical functioning and the ability to return to work[@b72] ^,^ [@b73]. It is also associated with increases in perceived control over pain and decreases in catastrophizing, self-reported patient disability, pain intensity and depression[@b74]. A meta-analysis of 65 studies, which evaluated the efficacy of multidisciplinary treatment for chronic back pain, concluded that this approach is superior to either conventional unimodal treatment or no treatment, with regard both to patients' subjective ratings of pain and to behavioral variables[@b67]. Moreover, there is evidence that these benefits are maintained for more than 10 years[@b75]. In one geographical region of Denmark, the annual rate of lumbar disc operations decreased by almost half following the establishment of two nonsurgical, multidisciplinary spine clinics, and the rate of elective, first-time disc surgeries decreased by approximately two thirds[@b62].

However, there is still evidence of a lack of consistency in the treatment of patients with chronic pain. Two recent longitudinal studies in the UK investigated the use of National Health Service resources by patients with chronic low back pain and osteoarthritis pain, from the perspective of primary care and secondary care pain clinics[@b76] ^,^ [@b77]. The primary care study found that most patients received a wide variety of pain medications with no overall prescribing pattern or treatment pathway[@b76]. Many received non-drug treatment, most frequently physiotherapy. The investigators concluded that chronic pain is managed through individualized patient pathways and that evidence-based guidelines for primary care treatment and referral are needed[@b76]. The secondary care study revealed wide variations between pain clinics in the source of referral, non-drug treatments, investigations requested and the duration of patients' registration, as a result of differences in local policies and structures[@b77]. Many patients received no non-drug treatment from the clinic. This study highlighted the lack of a clearly defined model of practice for specialist pain clinics[@b77].

The development of a standard set of quality indicators could reduce the variation between multidisciplinary pain management teams and lead to a higher overall standard of care. This might include assessment of:patient outcomes, in terms of reduced intensity and/or frequency of pain, improved physical and psychological functioning, quality of life and patient satisfactioncompliance with guidelines and evidence-based practices developed for specific patient populations, types of pain, and conditions or proceduresuse of standardized assessment instruments, such as the Short Form 36 and the McGill Pain Questionnairephilosophy and organizational strategy orientated towards continuous improvementquality and frequency of communication within the teammonitoring of team performance and the ready availability of appropriate education and training.

Conclusions {#ss15}
===========

It is important that everyone involved in the management of chronic pain understands the development of chronic pain and the pathophysiological processes involved. This is patently not the case at present and the consequences include poor diagnosis, inappropriate drug therapy, and neglect of concomitant symptoms such as anxiety and catastrophizing. The number of patients with chronic pain looks set to increase dramatically and improved training in pain management is clearly needed, starting with the undergraduate medical course. Even in developed countries the amount of time currently allocated to pain management is generally inadequate; in the UK, for example, the median time spent on pain management by a medical student is 13 hours, and sometimes as little as 6 hours[@b78]. When the undergraduate training of all healthcare professionals is analyzed, education about the identification, assessment and treatment of pain represents less than 1% of university-based teaching -- yet pain is the most common reason for patients to consult their general practitioner[@b78]. Continuing medical education must also play a part, and this review of the development of chronic pain and best clinical practice is intended to encourage further study by those who manage patients with chronic pain.
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